With a market cap driven by its obesity drugs, Eli Lilly is making multi-billion dollar acquisitions like Centessa that are mere "rounding errors" for its finances. This strategy allows it to buy into high-potential, next-generation therapeutic areas like the orexin space for a relatively low financial risk, diversifying beyond GLP-1s.

Contrary to seeking fully de-risked assets, pharmaceutical companies often prefer acquiring companies with some remaining clinical risk. This strategy allows them to leverage unique insights on early data to acquire assets at a better valuation, creating an opportunity for outsized returns before the value is obvious to others.

Standard pharmaceutical M&A playbook flushes acquired personnel and secondary pipeline assets to isolate lead candidates, which often later fail. Eli Lilly instead preserves acquired scientific teams and development baskets until proof of concept. Ricks notes that pharma acquirers cannot reliably pick which asset will generate value upfront, and keeping talent intact integrates vital scientific expertise into internal research leadership.

Eli Lilly's recent deal-making reveals an aggressive, multi-modal strategy. It secured an AI partnership for obesity (Nimbus), invested in an AI platform for oncology (InduPro), and spent $1.2B acquiring Ventix Biosciences for its oral inflammation pipeline, demonstrating a broad approach to securing leadership in its focus areas.

Luba Greenwood reframes competition in biotech as a positive force. When multiple companies pursue the same biological target, it validates the target's importance and accelerates discovery. This collaborative mindset benefits the entire field and, ultimately, patients, as the best and safest drug will prevail.

To prepare for its internally discovered drugs, Eikon Therapeutics first in-licensed external programs. This allowed their newly-formed clinical team, led by a Merck veteran, to build cohesion and processes on existing assets, avoiding the risk of testing their teamwork for the first time on novel, internally-developed molecules.

By acquiring both Kelonia (lentivirus) and Orna (RNA-based), Eli Lilly is strategically hedging its bets. This portfolio approach anticipates that different in vivo CAR-T delivery mechanisms will be optimal for different applications, such as durable lentivirus for cancer versus faster-acting RNA for autoimmune diseases.

Eli Lilly's aggressive acquisition spree across diverse therapeutic areas like psychedelics is a deliberate, long-term strategy. Dubbed 'Amazonification,' it aims to build a diversified portfolio to preempt the inevitable plateau of its obesity franchise, a proactive approach many successful companies neglect.

With 20 deals this year and only one in obesity, Eli Lilly is not just reinvesting in its core strength. It is leveraging massive cash flow to aggressively acquire early-stage (Phase 2 or earlier) and preclinical assets in new areas, a long-term luxury its competitors, who are constrained by near-term patent cliffs, cannot match.